Enteral supplementation with arachidonic and docosahexaenoic acid and pulmonary outcome in extremely preterm infants
Open Access
- 15 February 2024
- journal article
- research article
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 201, 102613
Abstract
No abstract availableKeywords
Funding Information
- Region Skåne
- Swedish Heart and Lung Association
- Swedish Society for Medical Research
- Knut and Alice Wallenberg Foundation
- Region Stockholm
- Magnus Bergvall Foundation
This publication has 29 references indexed in Scilit:
- Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of Bronchopulmonary Dysplasia in Preterm InfantsJAMA Network Open, 2023
- Comparison of New Bronchopulmonary Dysplasia Definitions on Long-Term Outcomes in Preterm InfantsThe Journal of Pediatrics, 2022
- Effect of Enteral Lipid Supplement on Severe Retinopathy of PrematurityJAMA Pediatrics, 2021
- Trends in Bronchopulmonary Dysplasia Among Extremely Preterm Infants in Japan, 2003-2016The Journal of Pediatrics, 2021
- Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia–Free Survival in Breastfed Preterm InfantsJAMA, 2020
- Arachidonic acid inhibits inflammatory responses by binding to myeloid differentiation factor-2 (MD2) and preventing MD2/toll-like receptor 4 signaling activationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Association Between Year of Birth and 1-Year Survival Among Extremely Preterm Infants in Sweden During 2004-2007 and 2014-2016JAMA, 2019
- The global epidemiology of preterm birthBest Practice & Research Clinical Obstetrics & Gynaecology, 2018
- Bronchopulmonary Dysplasia: Executive Summary of a WorkshopThe Journal of Pediatrics, 2018
- A Time-Based Analysis of Inflammation in Infants at Risk of Bronchopulmonary DysplasiaThe Journal of Pediatrics, 2018